Ibrutinib and Venetoclax Combo ‘Impressive’ in Front-Line CLL

The combination of two targeted therapies — ibrutinib (Imbruvika, Pharmacyclics/Janssen) and venetoclax (Venclexta, AbbVie) – has shown impressive results in the front-line treatment of chronic lymphocytic leukemia (CLL).

To read the full story visit Medscape